Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The neuronal nicotinic acetylcholine receptor subunit alpha-10 (CHRNA10) is a protein that primarily functions as part of a heteromeric ion channel complex, most commonly pairing with the alpha-9 subunit [1][3]. Unlike most other nicotinic receptors, the alpha-9/alpha-10 subtype is predominantly found in the peripheral nervous system, particularly in the cochlear hair cells of the inner ear and in various immune cells [1][4]. In the auditory system, these receptors mediate inhibitory feedback from the brain to the ear, protecting against noise-induced damage [3]. Beyond hearing, alpha-10-containing receptors have emerged as significant therapeutic targets for the treatment of chronic and neuropathic pain [2]. Research indicates that blocking these receptors with specific antagonists, such as certain conotoxins (e.g., Vc1.1), can provide potent analgesic effects without the side effects associated with opioids [2][3]. Additionally, their presence on immune cells suggests a role in modulating inflammatory pathways, making them a focus for research into anti-inflammatory therapies and certain types of cancer where the receptor is overexpressed [1][2]. Sources: [1] UniProt (Q9GZZ6) [2] Mohammadi & Christie (2014), PubMed [3] Gotti et al. (2013), PubMed [4] NCBI Gene (CHRNA10)
Antagonism of the alpha-9/alpha-10 heteromeric receptor complex to modulate pain signaling and inflammatory responses.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuronal nicotinic acetylcholine receptor subunit alpha-10 (CHRNA10) (CHRNA10).